Ropes Wealth Advisors LLC Purchases 119 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ropes Wealth Advisors LLC raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% in the third quarter, Holdings Channel reports. The fund owned 7,412 shares of the company’s stock after buying an additional 119 shares during the quarter. Ropes Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $2,016,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in IDXX. Price T Rowe Associates Inc. MD boosted its holdings in IDEXX Laboratories by 32.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,180,724 shares of the company’s stock valued at $875,749,000 after acquiring an additional 787,736 shares during the period. Nuveen Asset Management LLC boosted its holdings in IDEXX Laboratories by 27,381.7% during the second quarter. Nuveen Asset Management LLC now owns 568,322 shares of the company’s stock valued at $156,476,000 after acquiring an additional 566,254 shares during the period. Invesco Ltd. boosted its holdings in IDEXX Laboratories by 28.2% during the second quarter. Invesco Ltd. now owns 1,472,407 shares of the company’s stock valued at $405,398,000 after acquiring an additional 323,919 shares during the period. Marshall Wace North America L.P. boosted its holdings in IDEXX Laboratories by 72.8% during the second quarter. Marshall Wace North America L.P. now owns 698,227 shares of the company’s stock valued at $192,242,000 after acquiring an additional 294,186 shares during the period. Finally, Thoroughbred Financial Services LLC boosted its holdings in IDEXX Laboratories by 27,432.9% during the second quarter. Thoroughbred Financial Services LLC now owns 257,433 shares of the company’s stock valued at $25,743,000 after acquiring an additional 256,498 shares during the period. Institutional investors own 86.85% of the company’s stock.

In related news, insider Jonathan W. Ayers sold 62,097 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $279.57, for a total value of $17,360,458.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director M Anne Szostak sold 3,283 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $279.37, for a total transaction of $917,171.71. Following the completion of the transaction, the director now directly owns 584 shares of the company’s stock, valued at approximately $163,152.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,380 shares of company stock valued at $19,362,310. 2.70% of the stock is owned by corporate insiders.

Shares of NASDAQ IDXX traded down $2.02 during mid-day trading on Monday, hitting $252.72. The company had a trading volume of 24,411 shares, compared to its average volume of 445,642. The company has a debt-to-equity ratio of 3.76, a current ratio of 1.12 and a quick ratio of 0.80. The business’s 50-day simple moving average is $273.75 and its 200-day simple moving average is $268.85. IDEXX Laboratories, Inc. has a 12 month low of $176.11 and a 12 month high of $294.57. The firm has a market cap of $22.66 billion, a P/E ratio of 59.32 and a beta of 0.79.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $1.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.10. IDEXX Laboratories had a net margin of 17.99% and a return on equity of 405.71%. The business had revenue of $605.30 million during the quarter, compared to analysts’ expectations of $597.09 million. During the same quarter last year, the company earned $1.05 earnings per share. The firm’s revenue was up 11.0% on a year-over-year basis. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 4.8 EPS for the current year.

A number of equities research analysts have issued reports on the stock. ValuEngine cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Zacks Investment Research cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating and set a $267.00 target price for the company. in a research note on Monday. Stifel Nicolaus increased their target price on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. Guggenheim set a $310.00 target price on shares of IDEXX Laboratories and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research note on Monday, September 9th. They issued a “neutral” rating and a $277.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $289.57.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: Diluted Earnings Per Share

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.